

May 10, 2023

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Presentation of the research results of Healios' eNK cells at the 26th ASGCT

HEALIOS K.K. ("Healios") announces that we will make poster presentations of our research results on eNK cells* at the 26th Annual Meeting of The American Society of Gene & Cell Therapy ([ASGCT 26th Annual Meeting](#)) in Los Angeles from May 16 to 20, 2023.

We will present a poster for eNK cells. Please see below for details.

Date of presentation: Friday, May 19, 2023.

Venue: the Los Angeles Convention Center in Los Angeles, CA.

Poster Board No.: 1576

Title: HLCN061: An "Off-the-Shelf" Gene Engineered Human iPSC-Derived NK Cell Product for the Treatment of Solid Tumors

* eNK cells

(Development code: HLCN061)

Healios' eNK cells are an iPSC-derived NK cell therapy with several functional enhancements achieved through gene-editing including enhanced recognition of and cytotoxicity towards cancer, improved persistence, increased capability to migrate to and infiltrate solid tumors, and the ability to recruit host immune cells. Healios has succeeded in developing eNK cells through its own research and has confirmed the anti-tumor effect of eNK cells in mice engrafted with human lung cancer cells and human liver cancer cells. In joint research with [the National Cancer Center Japan](#) ("the NCCJ") Healios is evaluating the antitumor effect of eNK cells in a PDX mouse disease model created using the NCCJ's JPDX samples. Healios is also conducting joint research using eNK cells for hepatocellular carcinoma with [Hiroshima University](#) and for mesothelioma with [Hyogo Medical University](#). Healios is continuing with in vitro and in vivo testing of its eNK cell therapy in preparation for its first clinical trials. In addition to advancing eNK cells as a monotherapy and in combination with existing drugs, Healios is developing a dual CAR-eNK cell product, in which chimeric antigen receptors (CARs) that specifically recognize cancer antigens are introduced into the eNK to facilitate enhanced targeting of certain solid cancers.

About Healios:

Healios is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan, where it has established a proprietary, gene-edited "universal donor" induced pluripotent stem cell (iPSC) line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe

unmet medical need. Healios' lead iPSC-derived cell therapy candidate, HLCN061, is a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene editing. Its near-term pipeline includes the somatic stem cell product HLCM051, which has been evaluated in Japan in Phase 2/3 and Phase 2 trials in ischemic stroke and acute respiratory distress syndrome (ARDS), respectively. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

<https://www.healios.co.jp/en>

Contact:

IR & Finance and Accounting Division
HEALIOS K.K.

E-mail: ir@healios.jp